MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$800K
Free Cash flow
-$45,370K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of long-t...
Accounts payable and accrued exp...
Maturities of marketable securit...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Accounts receivable, net
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-23,574
-26,364
-33,347
-93,783
Restricted deposit
-
0
0
-1
Depreciation and amortization
75
75
80
152
Accrued financing on prepaid forward obligation
1,059
1,270
1,472
123
Amortization (accretion) on marketable securities
-26
75
160
1,640
Share-based compensation
4,627
3,130
3,027
5,802
Amortization of discount on long-term debt
1,974
99
-397
774
Amortization of right of use assets
577
604
559
941
Acquisitions of ipr&d
0
0
0
3,128
Inventory
4,457
8,123
1,213
-2,099
Accounts receivable, net
22,330
13,379
54
-653
Prepaid expenses and other current assets
4,858
2,550
67
3,210
Other non-current assets
2,332
-1,598
5,958
212
Accounts payable and accrued expenses
7,629
1,544
-4,789
3,531
Employee related accrued expenses
-3,679
2,402
-532
1,076
Other current liabilities
0
-1
-263
62
Uncertain tax positions
-
112
-
-
Lease liabilities
-53
1,333
-628
-1,344
Net cash used in operating activities
-45,316
-38,325
-42,270
-81,849
Purchases of marketable securities
24,780
539
8,721
68,140
Maturities of marketable securities
4,146
28,273
40,206
70,768
Purchases of property and equipment
54
17
87
185
Net cash used in investing activities
-20,688
27,717
31,398
2,443
Principal payments on finance leases
321
1,855
-
-
Proceeds from exercise of options into ordinary shares
179
1,343
302
327
Proceeds from issuance of long-term debt, net
65,346
0
0
-
Proceeds from pre-funded warrant issuance, net of issuance costs
-
-3
0
3
Proceeds from ordinary shares issuances, net of issuance costs
0
31,831
7,970
0
Net cash provided by financing activities
65,204
31,316
8,272
330
Decrease in cash and cash equivalents
-800
20,708
-2,600
-79,076
Cash, cash equivalents and restricted cash at beginning of period
112,095
91,386
173,062
-
Cash, cash equivalents and restricted cash at end of period
111,295
112,095
91,386
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
long-term debt, net
$65,346K
Proceeds from exercise of
options into ordinary...
$179K
Net cash provided by
financing activities
$65,204K
Canceled cashflow
$321K
Decrease in cash and cash
equivalents
-$800K
Canceled cashflow
$65,204K
Accounts payable and
accrued expenses
$7,629K
Share-based compensation
$4,627K
Amortization of discount on
long-term debt
$1,974K
Accrued financing on
prepaid forward...
$1,059K
Amortization of right of use
assets
$577K
Depreciation and
amortization
$75K
Amortization (accretion) on
marketable securities
-$26K
Maturities of marketable
securities
$4,146K
Principal payments on
finance leases
$321K
Net cash used in
operating activities
-$45,316K
Canceled cashflow
$15,967K
Net cash used in
investing activities
-$20,688K
Canceled cashflow
$4,146K
Net loss
-$23,574K
Accounts receivable, net
$22,330K
Prepaid expenses and
other current assets
$4,858K
Inventory
$4,457K
Employee related accrued
expenses
-$3,679K
Other non-current
assets
$2,332K
Lease liabilities
-$53K
Purchases of marketable
securities
$24,780K
Purchases of property and
equipment
$54K
Buy us a coffee
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)